Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akesis Pharmaceuticals has initiated dosing of patients in its placebo controlled Phase IIa trial for AKP-020, a novel vanadium compound, to test its safety and efficacy in patients with type 2 diabetes.
Subscribe to our email newsletter
dgd Research of San Antonio, Texas, now a member of Cetero Research, is conducting the Phase IIa, controlled US clinical trial. The trial will enroll a total of 21 diabetic patients at a single site measuring efficacy (using the gold-standard euglycemic-hyperinsulinemic clamping procedure), as well as pharmacokinetic parameters, safety and tolerability of AKP-020 in diabetic patients.
Jay Lichter, president and CEO of Akesis, said: “We are pleased to have reached this Phase IIa milestone. We are on track to complete enrollment and dosing according to schedule and anticipate announcing results when they become available.”